Estimation of Seroprevalence of Anti-Herpes Simplex Virus Type-1 IgG Among Healthy Blood Donors in Sakaka City, Aljouf, Saudi Arabia
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Brieflands
Abstract
Background: Herpes simplex virus type-1 (HSV-1) is a highly infectious neurotropic virus. The data on HSV-1 infection in Saudi Arabia, including the seroprevalence of HSV-1 antibodies, are scarce. Objectives: This is the first study to evaluate the prevalence of anti-HSV-1 immunoglobulin G (IgG) in donated blood in Sakaka, Aljouf, Saudi Arabia. Methods: A total of 300 donated blood samples were collected from the Blood Bank of Prince Mutaib Bin Abdulaziz Hospital in Sakaka. Sensitive and specific enzyme-linked immunosorbent assay (ELISA) was used to detect anti-HSV-1 IgG. A comparison of the age, gender, education, occupation, income, hand hygiene, travel history, and cupping practice of blood donors stratified for the extent of anti-HSV-1 IgG was made. Results: There was a low prevalence of anti-HSV-1 IgG (20%; n = 60/300). Moreover, 50.0% of IgG-positive participants were in the age group of 41 - 45 years, and 81.7% of the participants had a household income of < 10000 SAR (statistically highly significant; P < 0.001*). All the participants performed hand washing with soap before handling food and after using the toilet. Furthermore, IgG-positive participants had a bachelor’s degree (50.0%), were governmental employees (60.0%), were international travelers (50.0%), and practiced cupping (50.0%) with statistically significant associations (P < 0.05*). Conclusions: The current study’s findings support previous reports about the key importance of improving socioeconomic conditions and hygiene measures in reducing the spread of HSV-1. The present study provides an alarm regarding reaching the age of sexual debut without acquiring protective anti-HSV-1 immunoglobulins, consequently becoming more susceptible to acquiring HSV-1 infection through the genital route. These data support the urgent need to develop an effective anti-HSV-1 vaccine.